문유정 (한국과학기술연구원, 고려대학교)님 | 한빛사연구자 > 한빛사

한국과학기술연구원, 고려대학교

최종업데이트 2022.02.14.

Low-dose radiation generated ROS-activatable doxorubicin prodrug loaded liposome nanoparticles for triple-negative breast cancer treatment
- J. Control. Release, Feb 27 2026, S0168-3659(26)00152-5 | https://doi.org/10.1016/j.jconrel.2026.114750
- 2026-02
- 바이오·의료융합
- 한빛사논문
Self-assembled Peptide-derived Proteolysis-targeting Chimera (PROTAC) Nanoparticles for Tumor-targeted and Durable PD-L1 Degradation in Cancer Immunotherapy
- Angew. Chem.-Int. Edit., Nov 21 2024, | https://doi.org/10.1002/anie.202414146
- 2024-11
- 바이오·의료융합
- 한빛사논문
Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death
- Theranostics, Published 2022-1-31,12(5):1999-2014 | doi:10.7150/thno.69119
- 2022-01
- 바이오·의료융합
- 한빛사논문
Cancer-specific drug-drug nanoparticles of pro-apoptotic and cathepsin B-cleavable peptide-conjugated doxorubicin for drug-resistant cancer therapy
- Biomaterials, Available online 26 August 2020, 120347 | https://doi.org/10.1016/j.biomaterials.2020.120347
- 2020-08
- 바이오·의료융합
- 한빛사논문

연구자 ID

저자논문